Trajan was pleased to be a supporting sponsor and attend the BioMelbourne Network's 7th Connecting Women in Biotechnology Luncheon, with the inaugural Women in Leadership awards, on 22 May 2015.
Over 400 women from biotechnology, medical technology and healthcare technology filled Mural Hall in Melbourne for a great afternoon of networking and honoring the successes of leading women in the industry. The event was also supported by the State Government of Victoria, City of Melbourne, and industry organizations.
Dr Nina Webster, Commercial Director at Acrux, and Dr Debra Yin Foo, Partner and Patent and Trade Marks Attorney at Phillips Ormonde Fitzpatrick, were the surprise guest speakers who joined host Dr Krystal Evans, CEO of BioMelbourne Network, to share some insight into their personal journeys and career advice for women in the sector.
Photo: Women representing Trajan Scientific and Medical at the Connecting Women in Biotechnology Luncheon.
From BioMelbourne Network:
New Awards Recognise Women in Leadership in Biotech, Medtech and Healthcare Technology
Australian women do comparatively well in biotechnology, medtech and healthcare technology – with 11.1% of companies in the sector in the ASX 200 having female executive key management personnel and 11.9% in the ASX 500.
However, in recognition that these figures need to improve and to honor outstanding women in the sector, The BioMelbourne Network will, this Friday, announce its inaugural Women in Leadership Awards.
The winners of the two awards – the BioMelbourne Network 2015 Women in Leadership Award and the Emerging Women in Leadership Award - have been selected because of their leadership in their fields of expertise, the contributions to the industry, their roles as mentors, and to recognize those women who “take strategic risks, tenaciously pursue goals and have made outstanding contributions to innovation in the industry,” according to Dr Krystal Evans, CEO of BioMelbourne Network.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.